Co-Diagnostics Files 8-K

TL;DR

CODX filed an 8-K, check for updates.

AI Summary

Co-Diagnostics, Inc. filed an 8-K on June 14, 2024, reporting other events and financial statements. The filing details the company's corporate information, including its address in Salt Lake City, Utah, and its IRS Employer Identification Number. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates Co-Diagnostics, Inc. is providing updates to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing header and does not contain specific financial or operational details that would indicate high risk.

Key Players & Entities

• Co-Diagnostics, Inc. (company) — Filer
• Salt Lake City, Utah (location) — Principal executive offices
• 46-2609363 (identifier) — IRS Employer Identification Number
• 1-38148 (identifier) — Commission File Number

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CODX The Nasdaq Capital M

Filing Documents

• form8-k.htm (8-K) — 36KB
• ex99-1.htm (EX-99.1) — 17KB
• ex99-1_001.jpg (GRAPHIC) — 3KB
• 0001493152-24-023796.txt ( ) — 229KB
• codx-20240614.xsd (EX-101.SCH) — 3KB
• codx-20240614_lab.xml (EX-101.LAB) — 33KB
• codx-20240614_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2024 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification Number) 2401 S. Foothill Drive , Suite D , Salt Lake City , Utah 84109 (Address of principal executive offices) (801) 438-1036 (Issuer's telephone number) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share CODX The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01 Other Events. On June 14, 2024, Co-Diagnostics, Inc. issued a press release announcing that it had submitted to the FDA a 510(k) Application for the Co-Dx PCR Pro Platform. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No.: Description: 99.1 Press Release, dated June 14, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CO-DIAGNOSTICS, INC. Date: June 14, 2024 By: /s/ Brian Brown Name: Brian Brown Title: Chief Financial Officer (Principal Financial and Accounting Officer)

View Full Filing

View this 8-K filing on SEC EDGAR